Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
03/2009
03/19/2009WO2009033782A2 Use of a teprotide and optionally carbetocin to treat eg aids or idiopathic pulmonay fibrosis
03/19/2009WO2009033781A2 Use of k237 as therapeutic agent
03/19/2009WO2009033780A2 Use of growth hormone-releasing factor and/or k237 as a therapeutic agents
03/19/2009WO2009033778A2 Mage-3 antigen and others for use as a therapeutic agent
03/19/2009WO2009033777A1 Leuprolide analog as a therapeutic agent
03/19/2009WO2009033776A1 Use of a defensin peptide as a therapeutic agent
03/19/2009WO2009033775A2 Peptide alpmhir alone or in combination with peptide yvpfppf as therapeutic agent
03/19/2009WO2009033772A1 Use of a peptide as a therapeutic agent
03/19/2009WO2009033771A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033770A2 Calcitonin c-terminal flanking peptide for use as a therapeutic agent
03/19/2009WO2009033769A2 Use of cortistatin 14 and others as a therapeutic agent
03/19/2009WO2009033768A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033767A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033766A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033765A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033764A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033763A1 Nafarelin and carboxymethyl-phe-leu as therapeutic agents
03/19/2009WO2009033760A2 Use of fibronectin fragment (196-203 ) as a therapeutic agent
03/19/2009WO2009033759A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033758A2 Use of the peptide phpfhffvyk as therapeutic agent
03/19/2009WO2009033757A2 Use of mage-3 antigen (271-279) as a therapeutic agent
03/19/2009WO2009033754A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033751A2 Use of leu-enkephalin as a therapeutic agent
03/19/2009WO2009033750A2 Use of phm-27 alone or in combination with leu-enkephalin as a therapeutic agent
03/19/2009WO2009033749A2 Use of thymopentin as a therapeutic agent
03/19/2009WO2009033748A2 Use of osteostatin, alone or in combination with thymopentin, as a therapeutic agent
03/19/2009WO2009033747A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033746A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033745A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033744A1 Use of urodilatin as a therapeutic agent
03/19/2009WO2009033741A2 Use of lvv-hemorphin-6 and optionally af12198 as therapeutic agent(s)
03/19/2009WO2009033740A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033739A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033738A2 Use of glucagon (1-29) alone or in combination with neuropeptide w30 as a therapeutic agent
03/19/2009WO2009033736A2 Use of met-enkephalin as a therapeutic agent
03/19/2009WO2009033735A2 Use of melanin concentrating hormone and met-enkephalin as therapeutic agents
03/19/2009WO2009033734A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033733A2 Use of apeptide as a therapeutic agent
03/19/2009WO2009033732A2 Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent
03/19/2009WO2009033731A2 Use of a laminin peptide as a therapeutic agent
03/19/2009WO2009033730A2 Peptide gxgrgdspca as a therapeutic agent
03/19/2009WO2009033729A2 Therapeutic uses of gastrin- 1 and g- pen-grgdspca
03/19/2009WO2009033725A1 Use of human neuropeptide as a therapeutic agent
03/19/2009WO2009033724A1 Use of c-type natriuretic peptide, alone or incombination with neuropeptide af, as a therapeutic agent
03/19/2009WO2009033723A2 Use of aip2 as a therapeutic agent
03/19/2009WO2009033722A2 Use of a octreotide as a therapeutic agent
03/19/2009WO2009033721A2 Use of salusin beta alone or in combination with octreotide as a therapeutic agent
03/19/2009WO2009033720A1 Mastoparan for the treatment of diseases
03/19/2009WO2009033719A2 Use of a deslorelin and mastoparan as a therapeutic agent
03/19/2009WO2009033718A2 Use of anti -inflammatory peptide 1 as a therapeutic agent
03/19/2009WO2009033717A2 Use of gonadorelin as a therapeutic agent
03/19/2009WO2009033714A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033712A2 Use of melanotan ii as a therapeutic agent
03/19/2009WO2009033711A2 Use of glp-1 as a therapeutic agent
03/19/2009WO2009033710A1 Use of peptide yy, alone or in combination with glucagon-like peptide, for use in medicine
03/19/2009WO2009033707A2 Use of retrocyclin-1 as a therapeutic agent for the treatment of hcmv infections
03/19/2009WO2009033701A1 Use of urodilatin as a therapeutic agent
03/19/2009WO2009033700A1 Use of secretin and optionally urodilatin as therapeutic agents
03/19/2009WO2009033696A1 Use of a peptide pyx-1 as a therapeutic agent
03/19/2009WO2009033692A2 Use of the peptides fibrinopeptide a and pyx-i as a therapeutic agents
03/19/2009WO2009033690A1 Bfgf (119-126) for therapeutic applications
03/19/2009WO2009033689A1 Piperidone derivatives and medical uses thereof
03/19/2009WO2009033687A1 Spantide ii and bfgf (119-126) for therapeutic applications
03/19/2009WO2009033684A1 Minigastrin as a therapeutic agent
03/19/2009WO2009033681A2 Cyclo-argd as a therapeutic agent
03/19/2009WO2009033680A2 Galanin-like peptide alone or in combination with cyclo-argd as a therapeutic agent
03/19/2009WO2009033669A2 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys-oh as a therapeutic agent
03/19/2009WO2009033668A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033667A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033666A2 Use of parathyroid hormone ( 1-34 ) as anti-hiv agent
03/19/2009WO2009033665A2 Use of a rgd-peptide and/or parathyroid hormone (1-34 ) as anti-hiv agent
03/19/2009WO2009033664A1 Use of delta-endorphin as a therapeutic agent
03/19/2009WO2009033663A1 Use of fertirelin and delta-endorphin as therapeutic agents
03/19/2009WO2009033661A2 Use of rgdspasskp and optionally angiotensin ii as therapeutic agents in the treatment of eg s. pneumoniae infections
03/19/2009WO2009033660A2 Use of octreotide as a therapeutic agent
03/19/2009WO2009033658A1 (d-leu7 ) -histrelin as a therapeutic agent
03/19/2009WO2009033656A2 Use of follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumoniae infection
03/19/2009WO2009033269A1 Novel polysaccharide immunogens from alloiococcus otitidis and synthesis of a glycoconjugate vaccine thereof
03/19/2009WO2009033268A1 Novel polysaccharide immunogens from clostridium difficile
03/19/2009WO2009015446A3 Triazole derivatives as viral replication inhibitors
03/19/2009WO2009011007A3 Asymmetric liposomes and uses in medical field thereof
03/19/2009WO2009008913A3 P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease
03/19/2009WO2008156914A3 Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture
03/19/2009WO2008138878A3 Novel pyridopyrazine derivatives, process of manufacturing and uses thereof
03/19/2009WO2008136867A3 Chlamydia pneumoniae vaccine and methods for administering such a vaccine
03/19/2009WO2008110690A3 Novel indole derivatives, methods for preparing same, and use thereof particularly as antibacterial agents
03/19/2009WO2008005511A8 Novel inhibitors of hepatitis c virus replication
03/19/2009US20090076250 recognize selectively both Programmed Death 1 (PD-1) protein and a membrane protein co-existing with PD-1 on a cell membrane, and can transmit a suppressive signal of PD-1; for medical treatment and/or prevention of diseases caused by immune abnormality
03/19/2009US20090076153 Deuterium-enriched tigecycline
03/19/2009US20090076142 Use of the irritating principal oleocanthal in olive oil, as well as structurally and functionally similar compounds
03/19/2009US20090076138 Deuterium-enriched darunavir
03/19/2009US20090076133 Deuterium-enriched zanamivir
03/19/2009US20090076132 Antiviral compositions and methods of treatment
03/19/2009US20090076122 PARP Modulators and Treatment of Cancer
03/19/2009US20090076115 Photosensitizers for Targeted Photodynamic Therapy
03/19/2009US20090076100 Deuterium-enriched gsk625433
03/19/2009US20090076097 Deuterium-enriched atazanavir
03/19/2009US20090076094 Novel antibacterial compounds
03/19/2009US20090076071 Deuterium-enriched retapamulin
03/19/2009US20090076045 Non-nucleoside reverse transcriptase inhibitors
1 ... 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 ... 1798